Anti-Human CD257 (BAFF) (Tabalumab) – Dylight® 488
Antibody DetailsProduct DetailsReactive Species Cynomolgus Monkey ⋅ Human ⋅ Rabbit Host Species Human Expression Host HEK-293 Cells FC Effector Activity Active Immunogen Original antibody was raised against soluble human BAFF. Product Concentration 0.2 mg/ml Formulation This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. State of Matter Liquid Storage and Handling This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping 2-8°C Wet Ice Excitation Laser Blue Laser (493 nm) RRIDAB_2893909 Additional Reported Applications For Relevant Conjugates ? N IP WB ELISA Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Tabalumab. Tabalumab neutralizes soluble human, cynomolgus monkey, and rabbit BAFF. Additionally, Tabalumab neutralizes membrane-bound BAFF. This product is for research use only. Background Tabalumab is a human monoclonal anti-B-cell activating factor (BAFF) antibody intended for the treatment of autoimmune diseases and B cell malignancies.1 BAFF is a membrane-bound, type II transmembrane protein that belongs to the tumor necrosis factor (TNF) ligand family and is the ligand for BR3, TACI, and BCMA. BAFF is an immunostimulant necessary for maintaining normal immunity. This cytokine has also been shown to play an important role in the proliferation and differentiation of B cells. An inadequate level of BAFF leads to immunodeficiency whilst an elevated level of BAFF causes unusually high antibody production that results in the development of autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Additionally, BAFF has been found in renal transplant biopsies with acute rejection.2 Furthermore, BAFF may be a mediator of food-related inflammation, and is associated with multiple dietary ailments including celiac disease, insulin resistance, diabetes, and obesity.3 Interestingly, it is suspected that BAFF may be involved in non-IgE-mediated reactions because there is no known correlation between BAFF and IgE.4 More research is needed to unlock the enormous therapeutic potential for BAFF antagonists. This cost-effective, research-grade Anti-Human CD257 (BAFF) (Tabalumab) utilizes the same variable regions from the therapeutic antibody Tabalumab making it ideal for research projects. Antigen Distribution BAFF is expressed on various cell types including monocytes, dendritic cells and bone marrow stromal cells. Ligand/Receptor TACI, BCMA,APRIL ligand, BAFFR/BR3 PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars . Cancer . Cell Biology . Costimulatory Molecules . Immuno-Oncology . Immunology . Signal Transduction . Stem Cell Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Research-grade Tabalumab biosimilars are used as calibration standards or reference controls in pharmacokinetic (PK) bridging ELISA to enable quantitative measurement of drug concentration in serum samples. The typical approach for biosimilar PK assays is to establish a single ligand-binding ELISA method using a single analytical standard—commonly, the biosimilar itself—as the calibrator for both biosimilar and reference product samples. This standard is used to generate a calibration curve in assay validation; serum samples containing either the biosimilar or reference Tabalumab are then quantified against this curve. Key details on their use:
In summary: In PK ELISA bridging studies for Tabalumab, research-grade biosimilars serve as the standard for calibration curves and QC controls, enabling accurate, precise quantification of drug concentrations in serum, and supporting regulatory comparability studies between biosimilar and reference products. Standard flow cytometry protocols for validating expression levels or binding capacity of BAFF using a conjugated Tabalumab biosimilar (e.g., PE or APC-labeled) typically involve staining target cells with the labeled antibody and measuring fluorescence intensity to assess binding or surface expression. While explicit protocols for Tabalumab-PE/APC conjugates are not widely published, protocols for Tabalumab and related antibodies follow established principles in the field. Key protocol steps include:
Essential controls:
Example protocol based on published BAFF–Tabalumab binding studies:
Additional notes:
These steps align with standard practices for antibody-based flow cytometry analysis. Direct conjugation of Tabalumab biosimilar to PE or APC follows typical labeling protocols and does not alter fundamental workflow. Adapting for Tabalumab specificity ensures reliable BAFF detection on target cells. Biopharma companies typically perform a comprehensive range of analytical assays to confirm both the structural and functional similarity of a proposed biosimilar to the originator (reference) biologic. These studies adhere to stringent regulatory guidelines, comparing the biosimilar and the original drug across multiple critical quality attributes (CQAs), using highly sensitive and orthogonal analytical methods. Key Analytical Assays for Biosimilarity:
A rigorous head-to-head comparison across multiple lots of both the biosimilar and the reference product is standard, providing detailed evidence that any detected differences are not clinically meaningful. Leinco Biosimilars in Analytical Studies: Leinco Technologies acts as a supplier of well-characterized biosimilar reference materials. In biosimilar development, Leinco biosimilar proteins can serve as either:
This facilitates:
However, Leinco biosimilars are not typically used as direct "subjects" of regulatory comparability; instead, they support assay development, validation, or serve as auxiliary comparators when designing or troubleshooting analytical workflows. In summary, the analytical similarity exercise in biosimilar development is multifaceted, relying on structural, physicochemical, and functional analyses, often using commercial biosimilar proteins like those from Leinco as references or assay controls as part of this rigorous process. References & Citations1. Manetta, J. et al. (2014) J Inflamm Res. 7: 121–131 2. Clatworthy, MR. et al. (2013) Transplantation. 96(4): 413–420. 3. Lied, GA. and Berstad, A. (2011) Scand J Immunol. 73(1):1-7. 4. Büchler, JR. and Cano, MN. (1986) Jpn Heart J. 27(1):117-22. |
Formats Available
Prod No. | Description |
---|---|
LT1400 | |
LT1404 | |
LT1401 | |
LT1411 | |
LT1406 | |
LT1405 | |
LT1407 |
